When symptoms were described as lasting 2 days, only 31% of clinicians recommended treatment.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
The authors show how a relatively small serosurveillance scheme could complement traditional surveillance, enhancing epidemic understanding and forecast modeling.
The odds of a respiratory tract infection and any infection were lower in the SARS-CoV-2 group.
Treatment with oseltamivir was associated with an approximately 50% reduction in the incidence of serious neuropsychiatric events.
Only a small fraction examine whether these devices or systems reduce human infections or identify potential harmful emissions.
Of 41 children, 27% died within 3 days after symptom onset, 91% of them from cerebral herniation; only 1 had been vaccinated against flu.
Shipments come on the heels of a severe flu season and record deaths in children.
The drug's prevention efficacy was 76% in the 450-mg group, 61% in the 300-mg group, and 58% in the 150-mg group.
Secondary bacterial pneumonia rates were significantly higher in the RSV group.
Studies tied oseltamivir to lower odds of death, shorter hospital stays, and lower rates of readmission, and onradivir and oseltamivir to speedier symptom relief.
Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and flu-associated prescribing exceeding 20% in peak flu years.
